Morgan Stanley Assumes Coverage on Boston Scientific (BSX) with an Overweight
More News related to BSX
- Boston Scientific (BSX) volatility of 48 near nine-month lows
- Gabelli Upgrades Boston Scientific (BSX) to Buy
- David Moenning’s Daily State of the Markets: 6/26
- Boston Scientific (BSX) Announces Retirement of Jim Tobin and Appoints Ray Elliott as New President and CEO
- Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEO
Morgan Stanley assumes coverage on Boston Scientific (NYSE: BSX) with an Overweight.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a b range of interventional medical specialties, including interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, oncology, endoscope, urology, gynecology and neuromodulation.
Related Categories
New CoverageStocks Mentioned
+19.79Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
